Macquarie-backed, state-owned conglomerate China Resources (CR) is waiting for Australian regulatory approval to buy private equity house KKR's 45% stake in oncology group GenesisCare. CR wants to continue expanding Genesis in Western Europe and to tap the Chinese market with new hospital management contracts. The deal values the company at US$1.3bn.